PPO Database - onderzoekslijnen
|Onderzoekslijnen||Alle projecten||Alle publicaties en voordrachten||Instituten|
|Onderzoekslijn 26||Apoptosis and tumorgenesis|
|Omschrijving||The term apoptosis or programmed cell death defines a genetically encoded cell death program, which is morphologically
and biochemically distinct from necrosis or accidental cell death. The characteristic morphological signs of apoptosis
(cellular shrinkage, membrane blebbing, nuclear condensation and fragmentation) are the final results of a complex
biochemical cascade of events which is an integral part of physiological homeostasis. Techniques designed to identify,
quantitate and characterize apoptosis are numerous, but flow cytometry (FCM) remains the methodology of choice to study
the apoptotic cascade in relation to cell type, trigger and time. All FCM apoptosis assays described have a solid experimental basis and have been
used successfully in basic research on molecular and biochemical mechanisms of apoptosis. In various clinical settings the
ability to follow the apoptotic process in patient samples may offer the rationale for optimal treatment schedules.
Apoptosis, physiological cell death, has a major role in the pathogenesis of many diaseases, notably malignancies, degenerative conditions and diseases of aging. Present knowlegde about the mechanisms of apoptosis facilitates development of biologically targeted drugs directed at specific aberrations in the diseases tissues. Clinical medicine is to test the therapeutic potential of these substance.
Drugs currently under development are targeted at regulators of apoptosis, signal transduction, growth factors and growth factor receptors. This involves gene therapy and the application of antisense DNA fragments.
Recent results in biologically anticancer therapy are promising and leave space for more intensive tumour eradication by combining with traditional cytotoxic therapy.
It is to be expected that the years to come will see the development of a biological approach to the treatment of degenerative diseases by inhibition of apoptosis.
|Onderzoeksleider laboratorium||Prof.dr. I.(Istvan) Vermes|
|Mede-onderzoeksleiders||dr. H.R. Franke, gynaecoloog A. Tibbe, post-doc prof.dr. C. Haanen, hematoloog|
|Instituut||Medlon BV Enschede|
|Periode||1-2000 - 1-2011|